Five-year follow-up sustained remission with rituximab in a patient with focal segmental glomerulosclerosis: A case report

This case contributes to the growing evidence supporting rituximab's therapeutic potential in adult FSGS, while highlighting the need for randomized controlled trials to establish its efficacy and optimal use in this challenging patient population.